

The role of the tumour suppressor gene PTEN in the etiology of cancers of the female genital tract

by

Greta Dreyer

submitted in fulfilment of the requirements for
the degree of

Doctor of Philosophy

in the subject

**Obstetrics and Gynaecology
(Gynaecologic Oncology)**

at the

University Of Pretoria

**Supervisor: Prof BG Lindeque
Co-supervisor: Prof E Jansen van Rensburg**

April 2010

Abstrak

Die rol van die tumoronderdrukker geen PTEN in die etiologie van kankers van die vroulike genitale traktus

Fosforilering en defosforilering van die tirosien aminosure in proteïene speel 'n belangrike rol in die regulering van sellulêre prosesse in alle eukariotiese organismes. Dit sluit die regulering van selsikluskontrolle, groeikontrolle, sellulêre differensiasie sowel as genetiese en sinaptiese oordrag in. Dit word lank reeds gespekuleer dat die fosfatase-gene betrokke is in menslike karsinogenese, maar die PTEN geen is die eerste fosfatase geen wat bewys word om 'n ware tumoronderdrukker geen te wees. As basiese funksie defosforileer normale PTEN die kinases en inhibeer dit die kinase sinjaal kontrolepaaie wat deur integrien en groeifaktor beheer word.

Die sentrale hipotese van hierdie studie is dat PTEN 'n belangrike rol speel in tumore van die boonste genitale traktus. Die frekwensie van abnormaliteite in die koderingsareas van hierdie geen is bestudeer in spesifieke ginekologiese tumore en weefsels met die gebruik van polimerase kettingreaksie gebaseerde mutasie-analise. Die maligne tumore sowel as die mees verwante pre-maligne of benigne weefsel- of tumortipes wat beskikbaar was, is gebruik as navorsingsmateriaal om sodoende die verskillende vlakke van PTEN betrokkenheid in die ontwikkeling van neoplasie te demonstreer.

Intieme betrokkenheid van die PTEN geen is gevind in endometriële karsinogenese. PTEN mutasies is in hiperplasie gevind en dit was algemeen in endometrioiede karsinoom (54%). Patogene mutasies was baie meer algemeen in kanker as in hiperplasie (10%). Veelvuldige mutasies is in sommige laat stadium tumore aangetoon, wat suggereer dat reeds maligne selle meer genetiese mutasies oor tyd verkry. Alle tumore waar meer as een patogeniese mutasie gevind is het voorgekom by swart pasiënte. Die laaste twee bevindinge is uniek tot hierdie studie.

Selektiewe betrokkenheid van die PTEN geen is gevind in die ontwikkeling van sagte weefsel tumore van die uterus. PTEN mutasies is nie in benigne sagte weefsel tumore gevind nie en geen betekenisvolle betrokkenheid is in leiomiosarkome of endometriële stromale sarkome aangetoon nie. PTEN was egter betekenisvol betrokke in karsinosarkome van die uterus (13%) en veral in tumore met 'n endometrioïede epiteelkomponent waar mutasies in 17% gevind is. Hierdie bevinding is 'n hoogs betekenisvolle en unieke navorsingsbevinding wat die hipotese ondersteun dat hierdie tumore uit die endometrium ontstaan. Dit onderskryf ook die indruk dat 'n sterk band bestaan tussen hierdie geen en endometrioïede differensiasie, met morfologie sterk gekoppel aan sellulêre genetika.

Mutasie in die PTEN geen is aangetoon in ovariële endometrioïede karsinoom in ~29% van gevalle wat ondersoek is. Die bevinding bevestig PTEN betrokkenheid in karsinogenese in hierdie tumortipe. Weereens toon die resultaat dat PTEN betrokkenheid gekoppel is aan endometrioïede morfologie. Die ondersoek van benign of pre-maligne letsels in hierdie orgaan was nie voldoende om kommentaar oor die tydsberekening van mutasie te kan lewer nie.

Met alle tumortipes in ag genome, is daar 'n tendens aangetoon van minder PTEN mutasies in swart vroue. PTEN mutasies korreleer met endometrioïede histologie. In kombinasie bevestig hierdie resultaat 'n rasse-diskrepansie in die distribusie van tumourtipe of morfologie.

In opsomming is die bevinding van hierdie studie dat daar betekenisvolle dog hoogs selektiewe PTEN geen betrokkenheid in boonste genitale traktus tumore is. 'n Sterk en interessante verband is bevestig tussen genotipe en histologiese fenotipe. Hierdie resultate verbeter die begrip van karsinogenese en behoort 'n bydrae te lewer in die soeke na nuwe anti-neoplastiese middels.

Abstract

The role of the tumour suppressor gene PTEN in the etiology of cancers of the female genital tract

The phosphorylation and dephosphorylation of the tyrosine amino-acids in proteins play an important role in the regulation of many cellular processes in all eukariotic organisms, including the regulation of cell cycle control, growth control, cellular differentiation and gene and synaptic transmission. The involvement of the phosphatase genes in human carcinogenesis was long-suspected, but PTEN is the first important phosphatase gene proven to be a true tumour suppressor. The basic function of normal PTEN is the dephosphorylation of the kinases and inhibition of the integrin and growth factor mediated kinase signalling pathways.

The central hypothesis of this study is that PTEN plays an important role in tumours of the upper female genital tract. The involvement of aberrations in the coding regions of this gene was studied in specific gynaecologic tumours and tissues using polymerase chain reaction based mutation analysis. The research model was to study both the malignant tumour and the closest available pre-malignant or benign counterpart to demonstrate different levels of involvement of PTEN in the evolving steps.

The PTEN gene was found to be intimately involved in endometrial carcinogenesis. Involvement was demonstrated in hyperplasia and was common in endometroid carcinoma (54%). Pathogenic PTEN mutations were much more common in cancer than in hyperplasia (10%). Multiple mutations were found in some late stage tumours, suggesting that the already malignant tumour cells accumulate more genetic mutations over time. All tumours with more than one pathogenic mutation occurred in African patients. The latter two findings are unique to the current study.

Selective involvement of the PTEN gene was demonstrated in uterine soft tissue tumours. PTEN involvement was neither found in benign soft tissue tumours nor significantly in leiomyosarcoma or endometrial stromal sarcoma. However, PTEN plays a significant role in uterine carcinosarcoma (13%) and specifically in tumours with an endometrioid epithelial component, where mutations were found in 17%. This finding is a highly significant and unique research result which supports the hypothesis of the endometrial origin of these tumours. It also supports the observation of a strong link between this gene and endometrioid differentiation, with morphology strongly linked to cellular genetics.

PTEN gene mutation was demonstrated in ovarian endometrioid carcinoma in ~29% of cases investigated. This finding confirms PTEN involvement in carcinogenesis in this tumour type. The finding suggests that PTEN involvement is linked to endometrioid epithelial morphology. We could not sufficiently test the involvement of the gene in benign or pre-malignant ovarian endometrioid lesions and thus cannot comment on the chronology of mutations in this tissue type.

When all tumour types were included, there was a tendency towards a lower frequency of PTEN mutations in African women. PTEN mutations correlated with endometrioid histology. In combination, these results confirm the racial disparity in tumour type distribution or morphology.

In summary this study demonstrated significant though highly selective PTEN gene involvement and a strong and interesting association between genotype and histological phenotype was confirmed. The findings enhance our understanding of carcinogenesis and should lead to translational research into new anti-neoplastic drugs.

Short summary

The role of PTEN gene mutation in the evolution of gynaecologic malignancies was analysed using polymerase chain reaction based mutation analysis.

Benign, pre-malignant and malignant tumours of the upper female genital tract were examined. The accumulation of cellular genetic damage during carcinogenesis were studied and compared in the different tissue and tumour types.

The study demonstrated significant though highly selective PTEN gene involvement and a strong and interesting association between genotype and histological phenotype was confirmed.

The findings enhance our understanding of carcinogenesis and should lead to translational research into new therapies.

Contents

Abstrak	2
Abstract	4
Short summary	6
Contents	7
Chapter 1	16
The role of the tumour suppressor gene PTEN in the etiology of cancers of the female genital tract general introduction	
1 Introduction to the study	18
1.1 Background.....	18
1.2 Research questions.....	20
1.2.1 Endometrial hyperplasia and carcinoma	20
1.2.2 Uterine soft tissue tumours.....	21
1.2.3 Endometroid ovarian cancer	21
1.3 Objectives.....	22
2 Justification of the study	22
2.1 Motivation	22
2.2 Significance.....	23
3 Theory base and general literature overview	23
3.1. Genetic changes as part of the carcinogenetic process	23
3.1.1 DNA repair genes.....	24
3.1.2 Proto-oncogenes and oncogenes	25
3.1.2.1 Extra-cellular peptide growth factors with their cell membrane receptors.....	25
3.1.2.1.1 HER- 2/neu or C-erb B-2	25
3.1.2.1.2 Proto-oncogene bcl-2.....	26
3.1.2.1.3 Epidermal growth factor (EGF).....	26
3.1.2.1.4 C-fms	26
3.1.2.2 Cell membrane proteins (The ras oncogenes)	27
3.1.2.3 Nuclear transcription factors (Proto-oncogene c-myc).....	28
3.1.3 Tumour suppressor genes	28
Loss of heterozygosity	28
The ‘two hit’ genetic model for tumorigenesis.....	28
Tumour suppressor genes and the ‘two-hit’ model.....	29
3.1.3.1 The tp53-gene.....	30
3.1.3.2 The DCC gene.....	30
3.1.3.3 The retinoblastoma gene	31
3.1.3.4 The PTEN gene	31
3.2. The function of the phosphatases and kinases.....	31
3.2.1 Protein phosphatases and protein kinases.....	31
Protein kinase B/Akt	32

Other protein kinases and integrin signaling	34
3.2.2 The lipid kinases and phosphatases in the phospholipid pathway	35
3.3. PTEN: The tumour suppressor gene and its protein product	36
3.3.1 The isolation of PTEN as a novel tumour suppressor gene	36
3.3.2 PTEN as a protein phosphatase and lipid phosphatase	38
3.3.3 The interaction of PTEN with known kinases, phosphatases and growth factors	39
3.3.4 PTEN and the control of cellular growth	41
3.3.4.1 Arresting cells in G1	41
3.3.4.2 Induction of apoptosis	41
3.3.4.3 Effect on cell and soma size	42
3.3.5 Biological activities of PTEN not directly related to growth	42
3.3.5.1 Cell adhesion, the intracellular matrix and PTEN	42
3.3.5.2 Cell migration and cell proliferation	43
3.3.6 Interaction of PTEN with other tumour suppressor genes, oncogenes and chemotherapeutic agents.....	44
3.3.7 Interaction of PTEN with steroid hormone receptors	44
3.4 The involvement of PTEN in non-gynaecologic neoplasms	45
3.4.1 Brain tumours.....	45
3.4.2 Breast cancer	45
3.4.3 Other malignancies.....	46
3.5 The involvement of PTEN in the etiology of cancers of the female genital tract	46
3.5.1 Neoplasms of the uterine epithelium	47
3.5.2 Neoplasms of the uterine soft tissue	47
4 Delineation of the research.....	48
4.1 Tumours of the female genital tract.....	48
4.1.1 Etiology of tumours of the upper vs lower female genital tract	48
4.1.2 Models of neoplastic transformation	48
4.1.2.1 Neoplasms of the uterine epithelium.....	49
4.1.2.2 Neoplasms of the uterine soft tissue.....	50
4.1.2.3 Neoplasms of the ovarian epithelium	50
4.2 Methods to study the role of PTEN	51
4.2.1 Detecting somatic genetic mutation	51
4.2.2 Detecting the aberrant protein product.....	52
5 Conclusion.....	52
Chapter 2	54
The role of the tumour suppressor gene PTEN in the etiology of endometrial cancer and hyperplasia	
1. Introduction	57
1.1 Background.....	57
1.2 Research questions and hypothesis	60
2. Literature overview	61
2.1 Genetic changes in endometrial proliferative disorders.....	61
2.1.1 DNA repair genes and micro-satellite instability.....	61
2.1.2 Proto-oncogenes and oncogenes	62

2.1.2.1 K-ras	62
2.1.2.2 HER 2/neu or c-erbB-2	63
2.1.2.3 Bcl-2	63
2.1.2.4 C-fms	63
2.1.2.5 C-myc	64
2.1.3 Tumour-suppressor genes and onco-suppressor genes	64
2.1.3.1 P 53	64
2.1.3.2 DCC	65
2.1.3.3 Rb-gene	65
2.1.3.4 PTEN	65
2.2 Histology of endometrial proliferative disorders	65
2.2.1 Endometrial hyperplasia and precursors of endometrial cancer	65
2.2.1.1 Endometrial hyperplasia	65
2.2.1.2 Endometrial intra-epithelial neoplasia (EIN) or carcinoma (EIC)	66
2.2.2 Endometrial polyps	66
2.2.3 Endometrial cancer	67
2.2.3.1 Pathogenetic subtypes	67
2.2.3.2 Histological subtypes	68
2.3 PTEN gene and endometrial proliferative disorders	69
2.3.1 PTEN in normal endometrium	69
2.3.2 PTEN in endometrial hyperplasia	69
2.3.3 PTEN in progression to endometrial cancer	70
2.3.4 PTEN in endometrial cancer	71
2.3.4.1 Frequency of PTEN mutations in endometrial cancer	71
2.3.4.1.1 Germline mutations	71
2.3.4.1.2 Somatic mutations	71
2.3.4.2 PTEN gene inactivation by other methods	72
2.3.4.4 Association of PTEN with other genetic anomalies	73
2.3.4.5 PTEN mutations and the prognosis of endometrial cancer	74
2.3.4.6 PTEN in different population groups and races	74
3. Materials and methods	74
3.1 Materials	74
3.1.1 Sampling and clinical material	74
3.1.2 Histology reports	75
3.1.3 Tissue for DNA analysis	76
3.2 Methods	76
3.2.1 DNA extraction	76
3.2.2 DNA amplification	77
3.2.3 PTEN mutation analysis	77
3.2.3.1 Denaturing gradient gel electrophoresis (DGGE)	77
3.2.3.2 Single strand conformational polymorphism (SSCP)	79
3.2.3.3 Sequence analysis	79
4. Results	
4.1 Clinical data	80
4.2 Histology data	83
4.2.1 Histological type	83
4.2.2 Histological grade	84
4.3 Mutation screening	84

4.3.1 Denaturing gradient gel electrophoresis results	84
4.3.2 Single strand conformational polymorphism results	86
4.4 Sequence analysis	86
4.4.1 Disease causing mutations	86
In the Pretoria patients the following was found:	86
In the Utrecht patients the following was found:.....	86
In the endometrial hyperplasia subset of patients the following was found: ...	87
Mutation analysis in Pretoria subset	88
Exon 1	88
Exon 3	88
Exon 4	89
Exon 5	89
Exon 6	89
Exon 7	89
Exon 8	89
Mutation analysis in Utrecht subset.....	90
Exon 1	90
Exon 5	90
Exon 6	90
Exon 7	90
Exon 8	91
Exon 9	91
4.4.2 Mutations of unknown significance and polymorphisms	91
4.5 Correlation between clinical and molecular results.....	92
4.5.1 Correlation between PTEN gene mutations and clinical findings in the endometrial cancers	92
4.5.2 Correlation between PTEN gene mutations and histology findings in the endometrial cancers.....	93
5. Interpretation and discussion	95
5.1 Endometrial hyperplasia	95
5.2 Endometrial cancer	95
5.3 Limitations and recommendations for future research	97
Chapter 3	98
The role of the tumour suppressor gene PTEN in the etiology of uterine soft tissue tumours	
1 Introduction	101
1.1 Background.....	101
1.2 Research questions and hypothesis	103
2 Literature overview	104
2.1 Genetic changes in soft tissue tumours of the uterus	104
2.1.1 Chromosomal abnormalities in uterine leiomyomas and uterine sarcomas.....	104
2.1.1.1 Cytogenetic changes in uterine leiomyomas and sarcomas	104
2.1.1.2 Alterations of ploidy in uterine sarcomas.....	105
2.1.2 Involvement of specific genetic alterations in leiomyomas and leiomyosarcomas.....	106
2.1.2.1 High mobility group (HMG) proteins	106

2.1.2.2 CYP17 polymorphism.....	106
2.1.2.3 Fumarate hydratase (FH)	106
2.1.2.4 K-ras, C-myc	107
2.1.2.5 HER 2/neu or c-erbB-2 and Bcl-2.....	107
2.1.2.6 P 53	108
2.1.2.7 Microsatellite instability (MSI).....	108
2.1.2.8 PTEN.....	108
2.2. Histology, pathogenesis and prognosis of uterine soft tissue tumours ...	109
2.2.1 Uterine leiomyomas	109
2.2.2 Uterine sarcomas.....	111
2.2.2.1 Leiomyosarcoma	113
2.3 The PTEN gene and uterine leiomyomas and sarcomas	115
2.3.1 PTEN in normal endometrium and myometrium.....	115
2.3.2 Frequency of PTEN alterations in uterine leiomyomas and sarcomas.....	116
2.3.2.1 Germline mutations.....	116
2.3.2.2 Somatic mutations.....	116
3. Materials and methods	117
3.1 Materials	117
3.1.1 Sampling and clinical material.....	117
3.1.2 Histology reports	118
3.1.3 Tissue for DNA analysis	118
3.2 Methods	119
3.2.1 DNA extraction	119
3.2.2 DNA amplification.....	119
3.2.3 PTEN mutation analysis	120
3.2.3.1 Single Strand Conformational Polymorphism	120
3.2.3.2 Sequence analysis.....	121
4. Results	121
4.1 Clinical data	121
4.1.1 Age distribution	122
4.1.2 Menopausal status	122
4.1.3 Stage distribution	122
4.1.4 Symptoms	123
4.1.5 Differences between population groups.....	123
4.2 Histology data.....	125
4.2.1 Leiomyosarcoma.....	125
4.2.2 Carcinosarcoma	126
4.2.3 Endometrial stromal sarcoma	126
4.3 Mutation screening	126
4.3.1 Single Strand Conformational Polymorphism (SSCP) results	126
4.4 Sequence analysis	127
4.4.1 Non-malignant tissue samples	127
4.4.2 Leiomyosarcomas	127
4.4.3 Carcinosarcomas.....	128
4.4.4 Endometrial stromal sarcomas.....	129
4.4.5 Polymorphisms and pten-protein aberration	129
4.5 Correlation between clinical findings and molecular results.....	129

4.6 Correlation between histology findings and molecular results	130
5. Interpretation and discussion	131
5.1 Benign myometrium.....	131
5.2 Leiomyomas, leiomyosarcomas and endometrial stromal sarcomas	131
5.3 Carcinosarcomas	131
5.4 Strengths, limitations and recommendations	133

Chapter 4 134

The role of the tumour suppressor gene PTEN in the etiology of endometroid ovarian tumours

1 Introduction	137
1.1 Background.....	137
1.2 Research questions and hypothesis	139
2 Literature overview	140
2.1 Endometriosis as neoplasm and pre-malignant condition in the ovary ...	140
2.1.1 The etiology of endometriosis.....	140
2.1.2 The pathophysiology of endometriosis and ovarian cancer	141
2.1.3 The association between endometriosis and malignancy	143
2.1.3.1 Gynaecological cancer	143
2.1.3.2 Non-gynaecological cancer.....	145
2.1.4 Evidence that endometriosis can be a pre-malignant disease.....	145
2.1.5 The malignant potential of different forms of endometriosis	145
2.1.6 Endometriosis as a genetic disease	146
2.2 Histopathology of endometroid ovarian lesions and ovarian neoplasms	146
2.2.1 Endometriosis and related non-malignant lesions.....	147
2.2.2 Endometriosis related malignant lesions	148
2.2.3 Ovarian neoplasms	149
2.2.3.1 Ovarian endometroid carcinoma.....	150
2.2.3.2 Ovarian clear cell carcinoma.....	150
2.2.3.3 Mucinous adenocarcinoma and mullerian mucinous borderline tumour (MMBT).....	150
2.2.3.4 Endometrial stromal sarcoma.....	150
2.2.3.5 Other non-endometroid epithelial carcinomas.....	151
2.3 Genetic changes in endometriosis and ovarian neoplasms.....	151
2.3.1 Cytogenetic changes in endometriosis and ovarian carcinoma.....	152
2.3.2 Specific genetic alterations in endometriosis and ovarian carcinoma	152
2.3.2.1 K-ras	152
2.3.2.2 Beta-catenin.....	153
2.3.2.3 HER 2/neu or c-erbB-2	153
2.3.2.4 P 53	154
2.3.2.5 BRCA 1 and BRCA 2.....	155
2.3.2.6 Bcl-2	156
2.3.2.7 DNA repair genes, micro-satellite instability (MSI) and loss of heterozygosity (LOH).....	156
2.3.2.8 PTEN.....	157
2.3.2.9 Phenotype and genotype in ovarian cancer	157
2.4 The PTEN gene in endometriosis and ovarian neoplasms	158
2.4.1 PTEN germline mutations in ovarian cancer	158

2.4.2 PTEN somatic mutations and pten protein expression	158
2.4.3 PTEN in normal endometrium and ovary	159
2.4.4 PTEN in ovarian endometriosis	159
2.4.5 PTEN in ovarian epithelial cancer	160
2.4.6 PTEN and loss of heterozygosity (LOH).....	161
2.4.6.1 Frequency of LOH (10q23) in ovarian lesions	161
2.4.6.2 LOH (10q23) vs. PTEN mutations in ovarian lesions	162
2.4.6.3 Importance of LOH (10q23) in ovarian lesions	163
2.4.7 PTEN and other genetic changes.....	164
2.4.8 PTEN involvement in the genetic sequence of carcinogenesis	164
2.4.9 PTEN related genetic anomalies.....	165
2.4.9.1 The tyrosine kinase-signalling cascade	165
2.4.9.2 Akt or Protein kinase B (PKB).....	165
3. Materials and methods.....	166
3.1 Materials	167
3.1.1 Sampling and clinical material.....	167
3.1.2 Histology reports	167
3.1.3 Tissue for DNA analysis	168
3.2 Methods	168
3.2.1 DNA extraction	168
3.2.2 DNA amplification.....	168
3.2.3 PTEN mutation analysis	169
3.2.3.1 Sequence analysis.....	169
4. Results.....	169
4.1 Clinical data	169
4.1.1 Age distribution and population group	169
4.1.2 Menopausal status and associated disease.....	170
4.2 Histology data.....	171
4.2.1 Stage distribution and differentiation grade	171
4.2.2 Tumour size.....	172
4.3 Mutation screening	172
4.4 Sequence analysis	172
4.4.1 Non-malignant tissue samples	172
4.4.2 Endometroid ovarian carcinoma	173
4.4.3 Polymorphisms and pten-protein aberration	173
4.5 Correlation between PTEN gene mutations and clinico-pathological findings.....	173
5. Interpretation and importance	173
5.1 Ovarian endometriosis	173
5.2 Endometroid ovarian carcinoma.....	174
5.3 Epithelial ovarian carcinoma	174
5.4 Strengths, limitations and recommendations	175
Chapter 5	177
The role of the tumour suppressor gene PTEN in the etiology of cancers of the female genital tract: Concluding remarks	
1 Introduction	179

1.1 Background.....	179
1.2 Research questions and hypotheses	179
1.2.1 Research questions	179
1.2.1.1 Endometrial hyperplasia and carcinoma	180
1.2.1.2 Uterine soft tissue tumours	180
1.2.1.3 Endometroid ovarian cancer	181
1.2.2 Hypotheses	181
1.3 Outline.....	182
2 Research findings	182
2.1 Clinical findings.....	182
2.1.1 Age at diagnosis.....	182
2.2.2 Stage distribution	183
2.2 Histology findings	184
2.1.1 Differentiation grade	184
2.3 PTEN mutation analysis.....	185
2.3.1 Frequency of mutations	185
2.3.1.1 Endometrial carcinoma.....	185
2.3.1.2 Uterine soft tissue tumours	186
Carcinosarcoma.....	186
Leiomyosarcoma	186
Endometrial stromal sarcoma	186
Summary	187
2.3.1.3 Endometroid ovarian cancer	187
2.3.2 Timing of PTEN mutations and mutations in pre-cursor lesions.....	187
2.3.2.1 Endometrial carcinoma.....	187
2.3.2.2 Uterine soft tissue tumours.....	188
2.3.2.3 Endometroid ovarian cancer	189
2.3.3 Correlation with stage, type, grade and other genetic findings.....	190
2.3.3.1 Endometrial carcinoma.....	190
2.3.3.2 Uterine soft tissue tumours.....	191
2.3.3.3 Endometroid ovarian cancer	191
2.3.4 Differences between population groups.....	192
2.3.4.1 Endometrial carcinoma.....	192
2.3.4.2 Uterine soft tissue tumours.....	192
3 Hypothesis testing.....	192
3.1 Endometrial tumours	192
3.2 Uterine soft tissue tumours	193
3.3 Ovarian endometroid carcinoma	193
4 Contributions and limitations	193
4.1 The carcinogenetic model	193
4.1.1 Endometrial hyperplasia and endometrial carcinoma	194
4.1.2 Uterine leiomyoma and leiomyosarcoma	194
4.1.3 Uterine carcinosarcoma	194
4.1.4 Ovarian endometriosis and ovarian endometroid carcinoma	195
4.2 The female upper genital tract.....	195
4.3 PTEN involvement	196
4.3.1 Role of PTEN in the carcinogenetic pathway.....	196
4.3.2 PTEN mutation analysis	197

4.3.3 Alternative tests of PTEN involvement	197
4.3.3.1 Immunohistochemistry	197
4.4 Epigenetics vs genetics	198
4.4.1 Defining epigenetics	198
4.4.2 DNA methylation as part of epigenetics	199
4.4.3 MicroRNA and gene expression	200
4.4.4 Epigenetics and Knudson's theory	200
5. Impact of the study and recommendations	201
5.1 Impact	201
5.1.1 Molecular study	201
Molecular testing methods	201
Epigenetics	202
Combination of genetic alterations	202
5.1.2 Improved diagnosis and stratification	202
5.1.3 Predicting treatment response	203
5.1.4 Novel treatment and improved outcome	204
5.2 Recommendations	204
Bibliography	206